Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of efgartigimod alfa in Japan
jRCT2080225020Phase 3Completed
- Start
- Jan 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3 trial of efgartigimod alfa. Started Jan 2020; status: completed.
02
Drugs
efgartigimod alfa
Beyond the preview
Go deeper on jRCT2080225020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225020.